Home › Multiple Myeloma › Kentucky
Multiple Myeloma clinical trials in Kentucky
15 studies for Multiple Myeloma are looking for participants at sites in Kentucky.
Cities in Kentucky
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Norton Cancer Institute, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT04634552Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
- Norton Healthcare Cancer Center, Louisville
RecruitingObservational study
Ages 10 and older · All sexes · Updated Nov 3, 2026 · NCT06323447A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Norton Cancer Institute St. Matthews, Louisville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07280013Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT03761108A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Lexington
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 21, 2026 · NCT07735637Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Norton Women's and Children's Hospital, Louisville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT06297226A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Norton Healthcare, Inc., Louisville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04879043Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Joseph Radiation Oncology Resource Center, Lexington
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Flaget Memorial Hospital, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Joseph Hospital, Lexington
- and 4 more
RecruitingPhase 3
All ages · All sexes · Updated Jun 10, 2026 · NCT05561387CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Kentucky/ Markey Cancer Center, Lexington
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT05722418From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.